- Home
- BTQ vs CDNA Comparison
BTQ vs CDNA Comparison
Compare BTQ & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTQ
- CDNA
- Stock Information
- Founded
- BTQ 1983
- CDNA 1998
- Country
- BTQ Canada
- CDNA United States
- Employees
- BTQ N/A
- CDNA N/A
- Industry
- BTQ
- CDNA Medical Specialities
- Sector
- BTQ
- CDNA Health Care
- Exchange
- BTQ Nasdaq
- CDNA Nasdaq
- Market Cap
- BTQ 728.0M
- CDNA 712.2M
- IPO Year
- BTQ N/A
- CDNA 2014
- Fundamental
- Price
- BTQ $5.44
- CDNA $16.03
- Analyst Decision
- BTQ
- CDNA Buy
- Analyst Count
- BTQ 0
- CDNA 7
- Target Price
- BTQ N/A
- CDNA $26.00
- AVG Volume (30 Days)
- BTQ 5.3M
- CDNA 1.2M
- Earning Date
- BTQ 11-14-2025
- CDNA 11-04-2025
- Dividend Yield
- BTQ N/A
- CDNA N/A
- EPS Growth
- BTQ N/A
- CDNA N/A
- EPS
- BTQ N/A
- CDNA 1.22
- Revenue
- BTQ $405,988.00
- CDNA $357,998,000.00
- Revenue This Year
- BTQ $100.70
- CDNA $12.73
- Revenue Next Year
- BTQ $669.96
- CDNA $11.90
- P/E Ratio
- BTQ N/A
- CDNA $13.12
- Revenue Growth
- BTQ 35.72
- CDNA 14.46
- 52 Week Low
- BTQ $0.18
- CDNA $10.96
- 52 Week High
- BTQ $16.00
- CDNA $26.37
- Technical
- Relative Strength Index (RSI)
- BTQ N/A
- CDNA 55.60
- Support Level
- BTQ N/A
- CDNA $14.27
- Resistance Level
- BTQ N/A
- CDNA $17.09
- Average True Range (ATR)
- BTQ 0.00
- CDNA 0.89
- MACD
- BTQ 0.00
- CDNA 0.10
- Stochastic Oscillator
- BTQ 0.00
- CDNA 62.43
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.